An Open Label, Multi-centre Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
The purpose of this study is to allow continued use of pasireotide in patients who are on
pasireotide treatment in a Novartis-sponsored, Oncology Clinical Development & Medical
Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society